<DOC>
	<DOCNO>NCT00369824</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . Vaccination pre-teens adolescent , ideally sexual debut thus exposure oncogenic HPV , rational strategy prevention cervical cancer , HPV vaccination could complement exist pre-adolescent/adolescents platform . Therefore , Phase 3b study design evaluate safety immunogenicity co-administering Boostrix and/or Menactra GSK Biologicals ' HPV vaccine ( 580299 ) compare administration vaccine alone . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Evaluation Safety Immunogenicity Co-administering HPV Vaccine With Other Vaccines Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe , , comply requirement protocol enrol study . A female , include , 11 18 year age time first vaccination . Written inform consent obtain parents/legally acceptable representative subject write informed assent obtain subject subject le 18 year age , write informed consent obtain subject subject 18 year age . Healthy subject , establish medical history historydirected physical examination , enter study . Previously complete routine childhood vaccination diphtheria , tetanus pertussis disease , accord recommend vaccination schedule time . Subjects must negative urine pregnancy test . Subjects childbearing potential time study entry require abstinent use adequate contraceptive precaution 30 day prior vaccination . Subjects also require agree continue precaution two month completion vaccination series . Female subject reach menarche ( begin menstruate ) study therefore become childbearing potential require agree follow precaution . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period ( Month 12/13 visit ) , subject expose investigational noninvestigational product . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day dose vaccine . Administration routine vaccine 8 day first dose study vaccine allow . Enrolment defer subject outside specify window . A woman plan become pregnant , likely become pregnant planning discontinue contraceptive precaution study period two month last vaccine dose . Pregnant breastfeed woman . Previous vaccination HPV , plan administration HPV vaccine foreseen study protocol study period . previous administration component investigational vaccine Administration preschool booster diphtheria , tetanus , pertussis vaccine within previous five year . Administration diphtheriatetanus booster tetanusdiphteriaacellular pertussis ( Tdap ) vaccine within previous five year . Previous vaccination Neisseria meningitidis . Hypersensitivity latex . Cancer autoimmune disease treatment . History allergic disease reaction likely exacerbate component vaccine follow tetanus toxoid , diphtheria toxoid pertussiscontaining vaccine . History encephalopathy within seven day administration previous dose pertussis vaccine attributable another identifiable cause . Progressive neurologic disorder , uncontrolled epilepsy progressive encephalopathy . Temperature &gt; = 105°F within 48 hour receipt prior dose diphteria tetanupertussis ( DTP ) vaccine , due another identifiable cause . Collapse shocklike state within 48 hour receipt prior dose DTP vaccine . Seizures without fever within three day prior dose DTP vaccine . Severe Arthustype hypersensitivity reaction follow prior dose tetanus toxoid within previous 10 year . Previous history GuillainBarré syndrome . Any confirm suspected immunosuppressive immunodeficient condition Acute disease time enrolment . All vaccine administer person minor illness Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period .</criteria>
	<gender>Female</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HPV</keyword>
	<keyword>HPV , diptheria , pertussis , tetanus , meningitis</keyword>
</DOC>